Matrix metalloproteinase 12, asthma, and COPD.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.Clinical drug investigation · 2021
   Trial
2. Current Understanding of Asthma Pathogenesis and Biomarkers.Cells · 2022
   Review
3. Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play.International journal of molecular sciences · 2022
   Review
4. Circulating MMP-12 as Potential Biomarker in Evaluating Disease Severity and Efficacy of Sublingual Immunotherapy in Allergic Rhinitis.Mediators of inflammation · 2022
   Article
5. Chest circumference and birth weight are good predictors of lung function in preschool children from an e-waste recycling area.Environmental science and pollution research international · 2017
   Article
6. The Rotterdam Study: 2014 objectives and design update.European journal of epidemiology · 2013
   Article
7. Stage-dependent association of BDNF and TGF-β1 with lung function in stable COPD.Respiratory research · 2012
   Article

Corrections and comments

• Comment on
  MMP12, lung function, and COPD in high-risk populations.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as